Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Market Cap	56.54B
Revenue (ttm)	19.12B
Net Income (ttm)	5.46B
Shares Out	261.75M
EPS (ttm)	20.73
PE Ratio	10.42
Forward PE	10.83
Dividend	5.73 (2.63%)
Ex-Dividend Date	Aug 11, 2025

Volume	678,981
Average Volume	890,158
Open	215.50
Previous Close	218.00
Day's Range	213.50 - 217.50
52-Week Range	172.50 - 294.50
Beta	-0.06
RSI	44.53
Earnings Date	Aug 7, 2025

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.